A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration

A. Barak, D. Hauser, P. Yipp, Lawrence S Morse, B. Leigh, D. Kubo, Z. Goldberg, J. Earle, J. T. Handa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Effective treatment for neovascular age-related macular degeneration (AMD) is currently limited. Radiation therapy, a therapeutic approach with known antiangiogenic properties, has been investigated as a modality to prevent severe visual loss in AMD. Most of the studies using external beam radiation employed <25 Gy to the whole eye, which is below the dose of radiation that is toxic to the retina and optic nerve (∼50 Gy and ∼59 Gy, respectively). Stereotactic fractionated external beam radiation (St-EBR) is a method that allows radiation to be delivered to a small, defined area. We investigated the effects of St-EBR in incremental doses up to 40 Gy on neovascular AMD. Patients with clinical signs and fluorescein angiography demonstrating neovascular AMD, visual acuity (VA) better than 20/400 and ineligible for laser treatment (MPS criteria) or who refused to have laser photocoagulation were enrolled in the study. Each patient was treated with radiation at incremental dosages from 20 Gy to 40 Gy. After completion of the radiation course, all patients were followed-up at 3 and 7 weeks and 3, 6, and 12 months. Best-corrected VA (ETDRS), slit-lamp and fluorescein angiographic evaluations were performed at each visit. 94 eyes of 89 patients were treated from October 1997 to April 2000. The VA was 0.82 ± 0.35 before treatment, 0.83 ± 0.36 at 6 months, and 0.89 ± 0.33 at 12 months. No patients suffered any significant acute side effects. No significant benefits in either VA or in membrane size were derived from increasing the doses of radiation. Our results are consistent with trends of a palliative benefit of radiotherapy in neovascular AMD and support further investigation of radiotherapy. Since there is no evidence that therapeutic effectiveness is dose dependent, our data provide no justification for potentially dangerous escalations in radiation dosage for treating neovascular AMD.

Original languageEnglish (US)
Pages (from-to)827-831
Number of pages5
JournalBritish Journal of Radiology
Volume78
Issue number933
DOIs
StatePublished - Sep 2005

Fingerprint

Macular Degeneration
Radiation
Membranes
Visual Acuity
Radiotherapy
Lasers
Therapeutics
Radiation Dosage
Fluorescein Angiography
Light Coagulation
Poisons
Optic Nerve
Fluorescein
Retina

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration. / Barak, A.; Hauser, D.; Yipp, P.; Morse, Lawrence S; Leigh, B.; Kubo, D.; Goldberg, Z.; Earle, J.; Handa, J. T.

In: British Journal of Radiology, Vol. 78, No. 933, 09.2005, p. 827-831.

Research output: Contribution to journalArticle

Barak, A. ; Hauser, D. ; Yipp, P. ; Morse, Lawrence S ; Leigh, B. ; Kubo, D. ; Goldberg, Z. ; Earle, J. ; Handa, J. T. / A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration. In: British Journal of Radiology. 2005 ; Vol. 78, No. 933. pp. 827-831.
@article{e6a39fe55bfc47c18ef1f2cfbc3a154a,
title = "A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration",
abstract = "Effective treatment for neovascular age-related macular degeneration (AMD) is currently limited. Radiation therapy, a therapeutic approach with known antiangiogenic properties, has been investigated as a modality to prevent severe visual loss in AMD. Most of the studies using external beam radiation employed <25 Gy to the whole eye, which is below the dose of radiation that is toxic to the retina and optic nerve (∼50 Gy and ∼59 Gy, respectively). Stereotactic fractionated external beam radiation (St-EBR) is a method that allows radiation to be delivered to a small, defined area. We investigated the effects of St-EBR in incremental doses up to 40 Gy on neovascular AMD. Patients with clinical signs and fluorescein angiography demonstrating neovascular AMD, visual acuity (VA) better than 20/400 and ineligible for laser treatment (MPS criteria) or who refused to have laser photocoagulation were enrolled in the study. Each patient was treated with radiation at incremental dosages from 20 Gy to 40 Gy. After completion of the radiation course, all patients were followed-up at 3 and 7 weeks and 3, 6, and 12 months. Best-corrected VA (ETDRS), slit-lamp and fluorescein angiographic evaluations were performed at each visit. 94 eyes of 89 patients were treated from October 1997 to April 2000. The VA was 0.82 ± 0.35 before treatment, 0.83 ± 0.36 at 6 months, and 0.89 ± 0.33 at 12 months. No patients suffered any significant acute side effects. No significant benefits in either VA or in membrane size were derived from increasing the doses of radiation. Our results are consistent with trends of a palliative benefit of radiotherapy in neovascular AMD and support further investigation of radiotherapy. Since there is no evidence that therapeutic effectiveness is dose dependent, our data provide no justification for potentially dangerous escalations in radiation dosage for treating neovascular AMD.",
author = "A. Barak and D. Hauser and P. Yipp and Morse, {Lawrence S} and B. Leigh and D. Kubo and Z. Goldberg and J. Earle and Handa, {J. T.}",
year = "2005",
month = "9",
doi = "10.1259/bjr/17631422",
language = "English (US)",
volume = "78",
pages = "827--831",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "933",

}

TY - JOUR

T1 - A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration

AU - Barak, A.

AU - Hauser, D.

AU - Yipp, P.

AU - Morse, Lawrence S

AU - Leigh, B.

AU - Kubo, D.

AU - Goldberg, Z.

AU - Earle, J.

AU - Handa, J. T.

PY - 2005/9

Y1 - 2005/9

N2 - Effective treatment for neovascular age-related macular degeneration (AMD) is currently limited. Radiation therapy, a therapeutic approach with known antiangiogenic properties, has been investigated as a modality to prevent severe visual loss in AMD. Most of the studies using external beam radiation employed <25 Gy to the whole eye, which is below the dose of radiation that is toxic to the retina and optic nerve (∼50 Gy and ∼59 Gy, respectively). Stereotactic fractionated external beam radiation (St-EBR) is a method that allows radiation to be delivered to a small, defined area. We investigated the effects of St-EBR in incremental doses up to 40 Gy on neovascular AMD. Patients with clinical signs and fluorescein angiography demonstrating neovascular AMD, visual acuity (VA) better than 20/400 and ineligible for laser treatment (MPS criteria) or who refused to have laser photocoagulation were enrolled in the study. Each patient was treated with radiation at incremental dosages from 20 Gy to 40 Gy. After completion of the radiation course, all patients were followed-up at 3 and 7 weeks and 3, 6, and 12 months. Best-corrected VA (ETDRS), slit-lamp and fluorescein angiographic evaluations were performed at each visit. 94 eyes of 89 patients were treated from October 1997 to April 2000. The VA was 0.82 ± 0.35 before treatment, 0.83 ± 0.36 at 6 months, and 0.89 ± 0.33 at 12 months. No patients suffered any significant acute side effects. No significant benefits in either VA or in membrane size were derived from increasing the doses of radiation. Our results are consistent with trends of a palliative benefit of radiotherapy in neovascular AMD and support further investigation of radiotherapy. Since there is no evidence that therapeutic effectiveness is dose dependent, our data provide no justification for potentially dangerous escalations in radiation dosage for treating neovascular AMD.

AB - Effective treatment for neovascular age-related macular degeneration (AMD) is currently limited. Radiation therapy, a therapeutic approach with known antiangiogenic properties, has been investigated as a modality to prevent severe visual loss in AMD. Most of the studies using external beam radiation employed <25 Gy to the whole eye, which is below the dose of radiation that is toxic to the retina and optic nerve (∼50 Gy and ∼59 Gy, respectively). Stereotactic fractionated external beam radiation (St-EBR) is a method that allows radiation to be delivered to a small, defined area. We investigated the effects of St-EBR in incremental doses up to 40 Gy on neovascular AMD. Patients with clinical signs and fluorescein angiography demonstrating neovascular AMD, visual acuity (VA) better than 20/400 and ineligible for laser treatment (MPS criteria) or who refused to have laser photocoagulation were enrolled in the study. Each patient was treated with radiation at incremental dosages from 20 Gy to 40 Gy. After completion of the radiation course, all patients were followed-up at 3 and 7 weeks and 3, 6, and 12 months. Best-corrected VA (ETDRS), slit-lamp and fluorescein angiographic evaluations were performed at each visit. 94 eyes of 89 patients were treated from October 1997 to April 2000. The VA was 0.82 ± 0.35 before treatment, 0.83 ± 0.36 at 6 months, and 0.89 ± 0.33 at 12 months. No patients suffered any significant acute side effects. No significant benefits in either VA or in membrane size were derived from increasing the doses of radiation. Our results are consistent with trends of a palliative benefit of radiotherapy in neovascular AMD and support further investigation of radiotherapy. Since there is no evidence that therapeutic effectiveness is dose dependent, our data provide no justification for potentially dangerous escalations in radiation dosage for treating neovascular AMD.

UR - http://www.scopus.com/inward/record.url?scp=24344507345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344507345&partnerID=8YFLogxK

U2 - 10.1259/bjr/17631422

DO - 10.1259/bjr/17631422

M3 - Article

C2 - 16110105

AN - SCOPUS:24344507345

VL - 78

SP - 827

EP - 831

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 933

ER -